跳至主要内容
临床试验/NCT06145087
NCT06145087
已完成
不适用

Investigation of Short and Intermediate Term Effects of a Supplement Mix Designed to Target Ageing Mechanisms on Vascular Function in Healthy Middle-aged Participants (STAMINA Study)

University of Surrey1 个研究点 分布在 1 个国家目标入组 61 人2023年6月1日

概览

阶段
不适用
干预措施
Placebo
疾病 / 适应症
Healthy Aging
发起方
University of Surrey
入组人数
61
试验地点
1
主要终点
Change in flow-mediated dilation
状态
已完成
最后更新
3个月前

概览

简要总结

In the ageing society, extending the healthy lifespan is a major challenge and a healthy diet may play an import role in maintaining health throughout life. With increasing age cardiovascular function declines and large and small blood vessels change in various and complex ways and these changes may lead to many age-related diseases. On a molecular level, there are many mechanisms that are associated with ageing including cellular senescence, loss of proteostasis, altered cellular communication, genomic instability, epigenetic alterations, telomere shortening, deregulated nutrient sensing, stem cell exhaustion and protein crosslinking. Animal and human studies suggest that dietary supplements may be able to affect these mechanisms. What the effect of the NOVOS Core supplement is on cardiovascular functions is not known.

The aim of the present study is to investigate the short and intermediate term effects of a supplement mix designed to target ageing mechanism on vascular function in healthy middle-aged subjects. (STAMINA Study) The hypothesis is that the supplement will lead to acute and sustained changes in biomarkers of vascular function and health.

60 healthy middle-aged people will be recruited and randomly assigned to either daily intake of the NOVOS Core supplement (n=30) or placebo (n=30) for up to 6 months (3-6). The supplement (NOVOS Core) is a commercially available product and has 12 ingredients. It was developed and is provided together with the placebo by AgeLess Sciences LLC, a Public Benefit Corporation. The study will require 2 visits by participants during which non-invasive vascular exams will be performed, venous blood taken and spot urine sample collected. The primary endpoint is change in flow-mediated dilation, secondary endpoints are change in blood pressure, cholesterol, arterial stiffness, microvascular function cardiovascular risk SCORE and daily walking distance. Tertiary endpoints are changes in biomarkers of ageing as assessed in blood samples. Measurements will be taken on the first day before and 2 hours after ingestion of the first supplement or placebo. Participants will consume the supplement or placebo for 6 months and vascular exams and one blood draw will be repeated during the final visit.

注册库
clinicaltrials.gov
开始日期
2023年6月1日
结束日期
2025年12月19日
最后更新
3个月前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Principal Investigator
主要研究者

Prof Christian Heiss

Prof Dr

University of Surrey

入排标准

入选标准

  • Generally healthy. (Note: those with stable conditions that do not interfere with the study objectives/procedures will be included at the PI discretion).
  • \>40 years
  • Body mass index \>20 kg/m2
  • Systolic blood pressure \>=120 mmHg
  • Smartphone with step counter

排除标准

  • Symptoms of acute infection
  • Cardiac arrhythmias
  • Active malignancy
  • Clinical signs or symptoms of unstable cardiovascular disease (coronary artery disease, lower extremity artery disease, cerebrovascular disease). These include angina pectoris, dyspnoea, palpitation, syncope, claudication, active vasoactive medication.
  • Women who have been pregnant in the last three months, currently pregnant, preparing to become pregnant during the study, or breastfeeding.
  • Those that have undergone a change in hormone-based therapies such as, but not limited to, oral contraceptive pills or progesterone pills within the last 2 months. Progesterone releasing devices are considered hormone-based therapy. Spironolactone is not considered a hormone-based therapy.
  • Subjects who are unwilling or unable to comply with the requirements of the protocol.
  • Subjects who have a history of or a current psychological illness or condition that would interfere with their ability to understand and follow the requirements of the study in the opinion of the principal investigator.
  • Subjects with or who have recently experienced traumatic injury, infections, or major surgery at the discretion of the qualified investigator.
  • Subjects who are likely to start taking drugs/medication on a continuous basis or that will undergo surgery during the trial.

研究组 & 干预措施

Placebo

The placebo is provided together with the placebo by AgeLess Sciences LLC, a Public Benefit Corporation.

干预措施: Placebo

"NOVOS Core" supplement

The "NOVOS Core" supplement is a commercially available product and has 12 ingredients. It was developed and is provided together with the placebo by AgeLess Sciences LLC, a Public Benefit Corporation.

干预措施: "NOVOS Core" supplement

结局指标

主要结局

Change in flow-mediated dilation

时间窗: 6 months

Change in flow-mediated dilation with ultrasound (%)

次要结局

  • Change in LDL cholesterol(6 months)
  • Change in arterial stiffness(6 months)
  • Change in total cholesterol(6 months)
  • Change in systolic blood pressure(6 months)
  • Change in diastolic blood pressure(6 months)
  • Change in HDL cholesterol(6 months)
  • Change in daily walking distance(6 months)
  • Change in cardiovascular risk(6 months)
  • Change in cholesterol(6 months)

研究点 (1)

Loading locations...

相似试验